Draft: A Case-based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis

Friday Symposium Preceding the 62nd American Society of Hematology Annual Meeting

Friday, December 4, 2020

7–10 a.m. PST (9 a.m.–Noon CST)

Online (live-streamed from Rochester, Minnesota)


This program’s overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. Topics discussed will include:

  • Choosing the right type of factor assays for monitoring newer factor and non-factor products for hemophilia management.
  • The optimal role of newer technologies like next-generation sequencing for diagnosis of coagulation disorders.
  • The optimal laboratory evaluation of inherited platelet disorders.
  • An update on recent advances in the diagnosis of heparin-induced thrombocytopenia.
  • The role of measuring direct-acting oral anticoagulants.

Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.

Intended Audience

Hematologists, oncologists, pathologists, nurse practitioners, physician assistants, nurses, and laboratory scientists.



Upon completion of the conference, participants should be able to:

  • Recount the novel agents for management of hemophilia.
  • Identify the optimal assay for monitoring novel agents in hemophilia management.
  • Efficiently and cost-effectively utilize laboratory tests in the evaluation of patients with suspected heparin-induced thrombocytopenia.
  • Determine when and how to pursue platelet esoteric testing to diagnose congenital platelet disorders.
  • Discuss a practical approach to utilizing next-generation sequencing technology in coagulation disorders.
  • Identify the appropriate indication for measurement of direct-acting anticoagulants and their utility in patient management.

Level of Instruction



AMA PRA Category 1 CreditsTM

);">Jointly accredited provider of Inter-professional Continuing Education In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 3.0 P.A.C.E.® contact hours.

State of California

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for the State of California. This program has been approved for 3.0 contact hours.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Hematology) credit. This program has been approved for 3.0 contact hours.


Faculty Disclosure

As a provider accredited by ACCME, Mayo Clinic College of Medicine and Science (Mayo Clinic School of Continuous Professional Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.


Contact the Education Department at 800-533-1710 or 507-284-3156 or email mcleducation@mayo.edu.